Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Respironics Has Sweet Dreams In November As Stock Advances

This article was originally published in The Gray Sheet

Executive Summary

Increased investor visibility, strong obstructive sleep apnea sales and a smooth CEO transition helped Respironics achieve a 9.2% stock gain in November

You may also be interested in...



Respironics Class I recall

Firm announces voluntary recall of 5,293 ComfortGel sleep apnea nasal masks distributed from Sept. 5-15 because some products were shipped without an exhalation port for carbon dioxide. Without the port, patients could experience oxygen deficiency or suffocation, the Murrysville, Penn. firm says Dec. 3. Respironics alerted FDA of the issue in September, and maintains that 82% of the recalled masks have returned with less than 3% affected. The company initiated a Class I recall for computer-controlled ventilators this summer (1"The Gray Sheet" July 7, 2003, In Brief)...

Gen/Surg Panel Okays Dermal Fillers 6-3; Minority Patient Studies Proposed

Medicis/Q-Med plan to conduct a 100-patient, Phase IV study to evaluate Restylane non-animal stabilized hyaluronic acid-based wrinkle gel in "people of color," in accordance with FDA panel recommendations

Given Imaging Targeting M2A Reimbursement Beyond Obscure Bleeding

A BlueCross BlueShield TEC assessment supporting capsule endoscopy for Crohn's disease diagnosis furthers Given Imaging's efforts to obtain coverage for indications beyond obscure bleeding
UsernamePublicRestriction

Register

MT019483

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel